IL150222A0 - Pharmaceutical compositions containing a gepirone metabolite - Google Patents
Pharmaceutical compositions containing a gepirone metaboliteInfo
- Publication number
- IL150222A0 IL150222A0 IL15022200A IL15022200A IL150222A0 IL 150222 A0 IL150222 A0 IL 150222A0 IL 15022200 A IL15022200 A IL 15022200A IL 15022200 A IL15022200 A IL 15022200A IL 150222 A0 IL150222 A0 IL 150222A0
- Authority
- IL
- Israel
- Prior art keywords
- gepirone
- pharmaceutical compositions
- compositions containing
- gepirone metabolite
- metabolite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17268499P | 1999-12-20 | 1999-12-20 | |
US09/709,741 US6534507B1 (en) | 1999-12-20 | 2000-11-13 | Methods for treating psychological disorders using bioactive metabolites of gepirone |
PCT/US2000/034131 WO2001045687A2 (en) | 1999-12-20 | 2000-12-18 | Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150222A0 true IL150222A0 (en) | 2002-12-01 |
Family
ID=26868346
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15022200A IL150222A0 (en) | 1999-12-20 | 2000-12-18 | Pharmaceutical compositions containing a gepirone metabolite |
IL150222A IL150222A (en) | 1999-12-20 | 2002-06-13 | Pharmaceutical preparations containing Gifiron metabolism |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL150222A IL150222A (en) | 1999-12-20 | 2002-06-13 | Pharmaceutical preparations containing Gifiron metabolism |
Country Status (20)
Country | Link |
---|---|
US (1) | US6534507B1 (pt) |
EP (1) | EP1242061B1 (pt) |
JP (1) | JP4236407B2 (pt) |
KR (1) | KR100602976B1 (pt) |
CN (1) | CN1411375A (pt) |
AT (1) | ATE294572T1 (pt) |
AU (1) | AU776409B2 (pt) |
CA (1) | CA2395458C (pt) |
CZ (1) | CZ300429B6 (pt) |
DE (1) | DE60019968T2 (pt) |
ES (1) | ES2241683T3 (pt) |
HU (1) | HU228963B1 (pt) |
IL (2) | IL150222A0 (pt) |
MX (1) | MXPA02006146A (pt) |
NO (1) | NO323304B1 (pt) |
NZ (1) | NZ519554A (pt) |
PL (1) | PL200378B1 (pt) |
PT (1) | PT1242061E (pt) |
RU (1) | RU2282448C2 (pt) |
WO (1) | WO2001045687A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001295478A1 (en) * | 2000-08-22 | 2002-03-04 | Akzo Nobel N.V. | Active metabolite of gepirone |
US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
US20040000689A1 (en) * | 2002-06-28 | 2004-01-01 | Erh-Kun Lai | Dual-bit MONOS/SONOS memory structure with non-continuous floating gate |
CN1674904A (zh) | 2002-08-12 | 2005-09-28 | 布里斯托尔-迈尔斯斯奎布公司 | 用于羟基氮哌酮类的改进方法 |
US20050004105A1 (en) * | 2003-01-29 | 2005-01-06 | Emer Leahy | Treatment for a attention-deficit hyperactivity disorder |
TW200521125A (en) * | 2003-11-18 | 2005-07-01 | Bristol Myers Squibb Co | Continuous process for producing hydroxyazapirones by oxidation |
BRPI0419179A (pt) * | 2004-11-05 | 2007-12-18 | Fabre Kramer Pharmaceuticals I | formulação de alta dosagem de liberação prolongada de gepirona |
KR20110013385A (ko) * | 2008-05-08 | 2011-02-09 | 파브르-크래머 홀딩스. 인크 | 주의력 결핍 장애 및 성기능 장애의 치료를 위한 3-히드록시 게피론 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423049A (en) | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
US4956368A (en) | 1989-07-24 | 1990-09-11 | Bristol-Myers Company | Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione |
US5478572A (en) | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2000
- 2000-11-13 US US09/709,741 patent/US6534507B1/en not_active Expired - Lifetime
- 2000-12-18 AT AT00986449T patent/ATE294572T1/de active
- 2000-12-18 JP JP2001546426A patent/JP4236407B2/ja not_active Expired - Lifetime
- 2000-12-18 CN CN00817455A patent/CN1411375A/zh active Pending
- 2000-12-18 CZ CZ20022137A patent/CZ300429B6/cs not_active IP Right Cessation
- 2000-12-18 DE DE60019968T patent/DE60019968T2/de not_active Expired - Lifetime
- 2000-12-18 CA CA002395458A patent/CA2395458C/en not_active Expired - Lifetime
- 2000-12-18 IL IL15022200A patent/IL150222A0/xx unknown
- 2000-12-18 NZ NZ519554A patent/NZ519554A/en not_active IP Right Cessation
- 2000-12-18 HU HU0301831A patent/HU228963B1/hu unknown
- 2000-12-18 WO PCT/US2000/034131 patent/WO2001045687A2/en active IP Right Grant
- 2000-12-18 EP EP00986449A patent/EP1242061B1/en not_active Expired - Lifetime
- 2000-12-18 PL PL364936A patent/PL200378B1/pl unknown
- 2000-12-18 PT PT00986449T patent/PT1242061E/pt unknown
- 2000-12-18 MX MXPA02006146A patent/MXPA02006146A/es active IP Right Grant
- 2000-12-18 RU RU2002119400/14A patent/RU2282448C2/ru active
- 2000-12-18 AU AU22687/01A patent/AU776409B2/en not_active Expired
- 2000-12-18 ES ES00986449T patent/ES2241683T3/es not_active Expired - Lifetime
- 2000-12-18 KR KR1020027007927A patent/KR100602976B1/ko active IP Right Grant
-
2002
- 2002-06-13 IL IL150222A patent/IL150222A/en active IP Right Grant
- 2002-06-19 NO NO20022954A patent/NO323304B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU776409B2 (en) | 2004-09-09 |
ATE294572T1 (de) | 2005-05-15 |
HUP0301831A2 (hu) | 2003-09-29 |
IL150222A (en) | 2009-09-22 |
HU228963B1 (en) | 2013-07-29 |
NO20022954L (no) | 2002-06-19 |
CA2395458A1 (en) | 2001-06-28 |
EP1242061B1 (en) | 2005-05-04 |
RU2002119400A (ru) | 2004-01-27 |
US6534507B1 (en) | 2003-03-18 |
RU2282448C2 (ru) | 2006-08-27 |
WO2001045687A2 (en) | 2001-06-28 |
CZ300429B6 (cs) | 2009-05-20 |
KR20020082470A (ko) | 2002-10-31 |
EP1242061A2 (en) | 2002-09-25 |
NZ519554A (en) | 2005-01-28 |
ES2241683T3 (es) | 2005-11-01 |
PL200378B1 (pl) | 2008-12-31 |
PT1242061E (pt) | 2005-09-30 |
JP4236407B2 (ja) | 2009-03-11 |
PL364936A1 (en) | 2004-12-27 |
DE60019968T2 (de) | 2006-02-02 |
MXPA02006146A (es) | 2004-08-23 |
CA2395458C (en) | 2009-05-12 |
CZ20022137A3 (cs) | 2003-03-12 |
KR100602976B1 (ko) | 2006-07-20 |
WO2001045687A3 (en) | 2002-04-25 |
NO20022954D0 (no) | 2002-06-19 |
DE60019968D1 (de) | 2005-06-09 |
AU2268701A (en) | 2001-07-03 |
CN1411375A (zh) | 2003-04-16 |
NO323304B1 (no) | 2007-03-05 |
JP2004500362A (ja) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU711212B2 (en) | Methods for treating allergic disorders using (-) cetirizine | |
AU2002360462A1 (en) | Compositions containing both sedative and non-sedative antihistamines | |
KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
AR022085A1 (es) | Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
MXPA04002825A (es) | Derivados de quinolina como antagonistas de neuropeptido y. | |
IL149496A (en) | Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract | |
HUP0201275A2 (en) | Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound | |
KR20170007868A (ko) | Bcr-abl, c-kit, ddr1, ddr2 또는 pdgf-r 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 | |
US5627183A (en) | Methods for treating urticaria using optically pure (+) cetirizine | |
IL150222A0 (en) | Pharmaceutical compositions containing a gepirone metabolite | |
MY129450A (en) | Pharmaceutical composition | |
HUP0100024A2 (hu) | Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények | |
PE20011004A1 (es) | Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4 | |
RU2002118304A (ru) | Способ подавления чувства страха | |
CA2364178A1 (en) | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | |
MY143571A (en) | Eplerenone crystalline form | |
DE3867042D1 (de) | Pharmazeutische praeparate. | |
IL162983A (en) | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis | |
SE9904412D0 (sv) | Comminuted form | |
JPS5942316A (ja) | 睡眠障害治療剤 | |
FR2696741B1 (fr) | Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique. | |
WO2002072100A3 (en) | Pharmaceutical composition containing pde v inhibitors and surfactants | |
AU703690B2 (en) | Methods for treating allergic disorders using optically pure (+)cetirizine | |
EP1580193A3 (en) | Eplerenone crystalline form |